Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Repeated Dose, Active Control Drug, Parallel-group and Single-center Phase I Study of the Safety of Intravenous Administration of NI-071 in Comparison With Remicade® in Japanese Patients With Rheumatoid Arthritis Inadequately Treated With Methotrexate

NCT01567358 is registered in ClinicalTrials.gov with Nichi-Iko Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT01567358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01567358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Repeated Dose, Active Control Drug, Parallel-group and Single-center Phase I Study of the Safety of Intravenous Administration of NI-071 in Comparison With Remicade® in Japanese Patients With Rheumatoid Arthritis Inadequately Treated With Methotrexate
Lead sponsor
Nichi-Iko Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2012
Completion date
April 30, 2013
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis